Technavio has been monitoring the global proteinuria therapeutics market size and it is poised to grow by USD 81.83 million during 2019-2023, progressing at a CAGR of almost 3% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200601005478/en/
Technavio has announced its latest market research report titled Global Proteinuria Therapeutics Market 2019-2023 (Graphic: Business Wire)
Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Latest Free Sample Report on COVID-19 Impact
The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. AbbVie Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Merck Co. Inc., Novartis AG, Pfizer Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd. are some of the major market participants. Although the rising prevalence of associated risk factors will offer immense growth opportunities, the lack of curative therapies will challenge the growth of the market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The rising prevalence of risk factors associated with proteinuria has been instrumental in driving the growth of the market. However, the lack of curative therapies might hamper market growth.
Proteinuria Therapeutics Market 2019-2023: Segmentation
Proteinuria Therapeutics Market is segmented as below:
Product
ACE Inhibitors
ARBs
Other Therapeutics
Geography
North America
Europe
Asia
ROW
To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR32169
Proteinuria Therapeutics Market 2019-2023: Scope
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our proteinuria therapeutics market report covers the following areas:
Proteinuria Therapeutics Market size
Proteinuria Therapeutics Market trends
Proteinuria Therapeutics Market industry analysis
This study identifies the introduction of smartphone-based diagnosis and treatment as one of the prime reasons driving the proteinuria therapeutics market growth during the next few years.
Proteinuria Therapeutics Market 2019-2023: Vendor Analysis
We provide a detailed analysis of around 25 vendors operating in the Proteinuria Therapeutics Market, including some of the vendors such as AbbVie Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Merck Co. Inc., Novartis AG, Pfizer Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd. Backed with competitive intelligence and benchmarking, our research reports on the Proteinuria Therapeutics Market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
Register for a free trial today and gain instant access to 17,000+ market research reports.
Technavio's SUBSCRIPTION platform
Proteinuria Therapeutics Market 2019-2023: Key Highlights
CAGR of the market during the forecast period 2019-2023
Detailed information on factors that will assist proteinuria therapeutics market growth during the next five years
Estimation of the proteinuria therapeutics market size and its contribution to the parent market
Predictions on upcoming trends and changes in consumer behavior
The growth of the proteinuria therapeutics market
Analysis of the market's competitive landscape and detailed information on vendors
Comprehensive details of factors that will challenge the growth of proteinuria therapeutics market vendors
Table Of Contents :
EXECUTIVE SUMMARY
SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
MARKET SEGMENTATION BY PRODUCT
Market segmentation by product
Comparison by product
ACE inhibitors Market size and forecast 2018-2023
ARBs Market size and forecast 2018-2023
Other therapeutics Market size and forecast 2018-2023
Market opportunity by product
CUSTOMER LANDSCAPE
GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America Market size and forecast 2018-2023
Europe Market size and forecast 2018-2023
Asia Market size and forecast 2018-2023
ROW Market size and forecast 2018-2023
Key leading countries
Market opportunity
DECISION FRAMEWORK
DRIVERS AND CHALLENGES
Market drivers
Market challenges
MARKET TRENDS
Introduction of smartphone-based diagnosis and treatment.
Advent of novel therapies
Increasing awareness about renal disorders
VENDOR LANDSCAPE
Overview
Landscape disruption
Competitive scenario
VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
AbbVie Inc.
AstraZeneca Plc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co.
Merck Co. Inc.
Novartis AG
Pfizer Inc.
Sanofi
Takeda Pharmaceutical Co. Ltd.
Teva Pharmaceutical Industries Ltd.
APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200601005478/en/
Contacts:
Technavio Research
Jesse Maida
Media Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
